



Reduced diffusing capacity for carbon monoxide predicts borderline pulmonary arterial pressure in patients with systemic sclerosis

Keita Ninagawa¹ · Masaru Kato¹ · Hiroyuki Nakamura¹ · Nobuya Abe¹ · Michihito Kono¹ · Yuichiro Fujieda¹ · Kenji Oku¹ · Shinsuke Yasuda¹ · Hiroshi Ohira² · Ichizo Tsujino² · Tatsuya Atsumi¹

Received: 9 June 2019 / Accepted: 3 July 2019 / Published online: 6 July 2019
© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Abstract

Early intervention in pulmonary arterial hypertension associated with systemic sclerosis (SSc) may improve its prognosis. We aimed to establish an algorithm to detect mean pulmonary artery pressure (mPAP) > 20 mmHg using non-invasive examinations in SSc patients by modifying the DETECT algorithm. This study included SSc patients who underwent right heart catheterization (RHC) in our hospital during 2010–2018. Following variables were assessed for performance to predict mPAP ≥ 25 mmHg or > 20 mmHg; anti-centromere or U1-RNP antibody, plasma BNP level, serum urate level, right axis deviation, forced vital capacity (FVC)/diffusing capacity for carbon monoxide (DLCO) ratio, and tricuspid regurgitation velocity. Of 58 patients enrolled in this study, 24 had mPAP of ≥ 25 mmHg and 9 had mPAP of 21–24 mmHg. Among variables tested, only FVC/DLCO elevated similarly in patients with mPAP of ≥ 25 mmHg (median 2.5) and those with mPAP of 21–24 mmHg (median 2.5) compared to those with mPAP of ≤ 20 mmHg (median 1.5). Given the particularly good correlation between DLCO and mPAP of > 20 mmHg, each variable was weighted according to its odds ratio and the total weighted score was calculated. The total weighted score exhibited a good predictive performance for mPAP of > 20 mmHg with its sensitivity of 87.5% and specificity of 92%. Among conventional risk factors for PAH, decreased DLCO may predict mPAP > 20 mmHg with priority in SSc patients. Weighting DLCO may improve the performance of screening algorithm for early SSc-PAH.

Keywords Pulmonary arterial hypertension · Systemic sclerosis · Screening · FVC/DLCO

Electronic supplementary material The online version of this article (<https://doi.org/10.1007/s00296-019-04370-0>) contains supplementary material, which is available to authorized users.

✉ Masaru Kato
ktmasaru@med.hokudai.ac.jp

Keita Ninagawa
k.ninagawa27@gmail.com

Hiroyuki Nakamura
nakahiro@med.hokudai.ac.jp

Nobuya Abe
anobuya@med.hokudai.ac.jp

Michihito Kono
m-kono@med.hokudai.ac.jp

Yuichiro Fujieda
edaichi@med.hokudai.ac.jp

Kenji Oku
kenoku@med.hokudai.ac.jp

Shinsuke Yasuda
syasuda@med.hokudai.ac.jp

Hiroshi Ohira
qqyr4ecy9@forest.ocn.ne.jp

Ichizo Tsujino
itsujino@nifty.com

Tatsuya Atsumi
at3tat@med.hokudai.ac.jp

¹ Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, N15W7, Kita-ku, Sapporo, Japan

² First Department of Medicine, Hokkaido University Hospital, Sapporo, Japan

Introduction

Pulmonary arterial hypertension (PAH) is an increased blood pressure in the pulmonary arteries and affects the right side of the heart, defined as a mean pulmonary artery pressure (mPAP) of ≥ 25 mmHg and a pulmonary artery wedge pressure of ≤ 15 mmHg. PAH occurs as an idiopathic disease of the pulmonary arterioles or as a complication of various diseases, with a particularly high prevalence in patients with systemic sclerosis (SSc). SSc-PAH is of great clinical significance because of its high mortality. Despite the recent development of pulmonary vasodilators, the median survival in SSc-PAH remains short at only 4 years [1]. Poor outcome of SSc-PAH may be partially explained by disease-related comorbidities, but also by delay in diagnosis [2]. Early detection of PAH is, therefore, critical to improve the outcome of those patients [3].

The diagnosis of PAH can only be made by right heart catheterization (RHC), but RHC is not appropriate for screening of PAH because of its invasiveness. From the European group, an evidence-based algorithm to screen SSc-PAH using non-invasive variables was published according to one clinical trial, namely DETECT study [4]. The DETECT algorithm includes a step-wise process in which non-echocardiographic variables are assessed first, with subsequent assessment of echocardiographic parameters. RHC is then recommended in high-risk patients. Other cohorts have validated the high sensitivity and negative predictive value of the DETECT algorithm [5, 6].

Recent data have supported that mPAP of 21–24 mmHg, called borderline PAP, in SSc patients have been considered as an early stage of SSc-PAH to be potentially treated [7]. The diagnostic cut-off level of mPAP is suggested to decrease to > 20 mmHg from ≥ 25 mmHg in SSc-PAH to enable the early intervention and improve the outcome [8]. Therefore, a new strategy to screen SSc with mPAP of > 20 mmHg is required. This study aimed to predict mPAP of > 20 mmHg using non-invasive variables in SSc patients by modifying the DETECT algorithm.

Patients and methods

Patients

This cross-sectional study involved a cohort of consecutive SSc patients who underwent RHC with suspicion of PAH from July 2010 to July 2018 in our hospital. RHC was performed in patients with unexplained dyspnea. The results of laboratory examinations were not considered for decision of performing RHC. SSc was diagnosed based on the

2013 American College of Rheumatology criteria. Patients were excluded if they had interstitial lung disease with a forced vital capacity (FVC) $< 60\%$ of predicted, renal insufficiency, pulmonary embolism, left heart disease such as left-ventricular systolic dysfunction, left-ventricular diastolic dysfunction, valvular disease, obstructive/congenital cardiomyopathies and congenital/acquired pulmonary vein stenosis, or pulmonary artery wedge pressure of > 15 mmHg. The study was performed in accordance with the Declaration of Helsinki and the principles of Good Clinical Practice. Approval was obtained from the Local Ethics Committee (Approval number: 17-0327). Patients' privacy data were strictly protected. Informed consent was obtained from all individual participants included in the study.

Methods

All data were extracted from the medical records. We adopted the following risk factors of having PAH in SSc patients with reference to the DETECT study [4]; anti-centromere or U1-RNP antibody, plasma BNP level, serum urate level, right axis deviation, FVC/diffusing capacity for carbon monoxide (DLCO) ratio, and tricuspid regurgitation velocity (TRV).

Cut-off levels of these factors were defined to maximize Youden Index with sensitivity of more than 70% using ROC curve. Screening performance of each factor was expressed as area under ROC curve (AUC), sensitivity, specificity, and odds ratio.

Statistical analysis

Continuous variables were expressed as median [min–max or quartile] and compared using Wilcoxon's test. Categorical variables were expressed as number (percentage) and compared using the Chi-square test. Statistical significance was defined as the probability value less than 0.05. All analyses were performed using the JMP Pro software (ver. 14.0; SAS Institute Inc., Cary, NC, USA).

Results

Patient characteristics

In total, 58 patients including 51 females and 7 males were enrolled in this study; 24 patients (41%) had mPAP of ≥ 25 mmHg, 9 (16%) had mPAP of 21–24 mmHg, and 25 (43%) had mPAP of ≤ 20 mmHg. Patient characteristics are summarized in Table 1 and Supplementary Table 1. Plasma BNP level was significantly higher in patients with mPAP of ≥ 25 mmHg (median 120 pg/mL, $p=0.03$) than those with

Table 1 Patient characteristics

	Total (n=58)	mPAP ≥ 25 mmHg (n=24)	25 mmHg > mPAP > 20 mmHg (n=9)	20 mmHg ≥ mPAP (n=25)	p value ^a
Age, years [min–max]	62 [49–70]	58 [49–70]	60 [57–67]	65 [47–73]	0.76
Female, n (%)	51 (88%)	21 (88%)	9 (100%)	21 (84%)	0.27
Anti-centromere antibody, n (%)	17 (29%)	6 (25%)	4 (44%)	7 (28%)	0.56
Anti-U1-RNP antibody, n (%)	23 (40%)	10 (42%)	4 (44%)	9 (36%)	0.88
Plasma BNP (pg/mL), median [quartile]	73 [25–169]	120 [54–222]	35 [22–79]	61 [14–176]	0.03
Serum urate (mg/dL), median [quartile]	5.2 [4.4–6.5]	5.3 [4.9–7.1]	4.5 [4.2–5.6]	4.5 [4.0–6.0]	0.10
Right axis deviation, n (%)	17 (29%)	15 (63%)	1 (11%)	1 (4%)	< 0.01
FVC/DLCO, median [quartile]	1.9 [1.5–2.7]	2.5 [1.7–3.6]	2.5 [2.4–2.9]	1.5 [1.3–2.0]	< 0.01
TRV (m/s), median [quartile]	3.1 [2.7–3.7]	3.7 [3.3–4.3]	3.1 [2.4–3.3]	2.7 [2.4–3.0]	< 0.01

FVC/DLCO forced vital capacity/diffusing capacity for carbon monoxide, mPAP mean pulmonary artery pressure, TRV tricuspid regurgitation velocity

^aContinuous variables were compared using Wilcoxon's test, and categorical variables using the Chi-square tests

mPAP of ≤ 20 mmHg (median 61 pg/mL), but did not differ statistically in those with mPAP of 21–24 mmHg (median 35 pg/mL). Serum urate level was not different among the groups. Right axis deviation (electrical axis > +110 in electrocardiogram) was found in 63% of patients with mPAP of ≥ 25 mmHg, whereas it was less frequent in patients with mPAP of 21–24 mmHg (11%) or ≤ 20 mmHg (4%). Interestingly, FVC/DLCO elevated similarly in patients with mPAP of ≥ 25 mmHg (median 2.5) and those with mPAP of 21–24 mmHg (median 2.5) compared to those with mPAP of ≤ 20 mmHg (median 1.5).

Predictive value of each factor for mPAP ≥ 25 mmHg or > 20 mmHg

AUC, cut-off value, sensitivity, specificity, and odds ratio of each risk factor to predict mPAP ≥ 25 mmHg or > 20 mmHg are summarized in Table 2. AUC was calculated in the quantitative values including plasma BNP level, serum urate level, and FVC/DLCO. AUC of plasma BNP level (0.70–0.61) and that of serum urate level (0.67–0.63) both decreased if the cut-off level of mPAP was sifted

from ≥ 25 mmHg to > 20 mmHg; conversely, AUC of FVC/DLCO did not decrease (0.71–0.80). Among the qualitative values including autoantibodies and right axis deviation, the latter had a high specificity (0.94 and 0.96, respectively) and a high odds ratio (26.7 and 22.2, respectively) for both mPAP ≥ 25 mmHg and > 20 mmHg. These results indicate FVC/DLCO and right axis deviation as important factors with priority to predict mPAP > 20 mmHg.

A pilot algorithm to detect early pulmonary hypertension (mPAP > 20 mmHg) in SSc patients

Finally, we made a pilot algorithm to detect mPAP > 20 mmHg in SSc patients. Prior to the development of algorithm, we weighted each non-echocardiographic factor based on its odds ratio (Table 2). The weighted score was approximately half value of the odds ratio. Compared to the number of positive risk factors, the total weighted score showed a higher predictive value for mPAP > 20 mmHg (AUC 0.84 vs 0.88) (Fig. 1a, b). If the cut-off value was set as five, the sensitivity and the specificity of the total weighted score were 97% and 52%, respectively. By adding

Table 2 Predictive value of each factor for mPAP ≥ 25 mmHg or > 20 mmHg

	mPAP ≥ 25 mmHg					mPAP > 20 mmHg					
	AUC	Cut-off	Sensitivity	Specificity	Odds ratio	AUC	Cut-off	Sensitivity	Specificity	Odds ratio	Weighted score
Autoantibodies ^a	–	Positive	0.67	0.29	0.8	–	Positive	0.72	0.36	1.4	1
Plasma BNP (pg/mL)	0.70	79.3	0.71	0.66	4.8	0.61	24.8	0.85	0.35	3.1	2
Serum urate (mg/dL)	0.67	4.9	0.83	0.53	5.5	0.63	4.5	0.82	0.44	3.6	2
Right axis deviation	–	Positive	0.63	0.94	26.7	–	Positive	0.48	0.96	22.2	11
FVC/DLCO	0.71	1.47	1.00	0.32	–	0.80	1.78	0.78	0.72	9.1	5

^aAnti-centromere antibody and/or anti-U1-RNP antibody. The weighted score is approximately half value of odds ratio




Fig. 1 Predictive value of three different algorithms for mPAP > 20 mmHg in SSc patients. **a** The number of positive non-echocardiographic risk factors including anti-centromere and/or U1-RNP antibody, plasma BNP > 24.8 pg/mL, serum urate > 4.5 mg/

dL, right axis deviation and FVC/DLCO > 1.78. **b** The total weighted score. Weighted score of each non-echocardiographic risk factor is described in Table 2. **c** Addition of TRV (cut-off 2.8 m/s, weighted score 4) to (**b**)

TRV (cut-off 2.8 m/s, weighted score 4) to the non-echocardiographic factors, AUC of the total weighted score further increased to 0.92 (Fig. 1c). When the cut-off value was set as 11, the sensitivity and the specificity were 87.5% and 92%, respectively. The detail of our final algorithm is described in Supplementary Fig. 1.

Discussion

In this study, we demonstrated increased FVC/DLCO and right axis deviation as important factors to predict mPAP > 20 mmHg in SSc patients. Considering the relatively low sensitivity of right axis deviation (48%), FVC/DLCO may be more feasible to predict mPAP > 20 mmHg in clinical settings.

Substantial numbers of SSc patients with borderline PAP are thought to be preceding stage and to easily progress to SSc-PAH [7]. In the PHAROS cohort study comprising SSc patients with borderline or normal PAP, 2 year follow-up showed that 55% of patients with borderline PAP developed PAH [9]. Another cohort study also showed that SSc patients with borderline PAP were more likely to develop PAH in the follow-up period than those with normal PAP [7]. Pulmonary arteriopathy of SSc progresses gradually and silently, although it worsens rapidly and critically once PAH

developed. Previous studies have suggested that early intervention in the disease course may give us potential benefit. Patients with SSc-PAH identified in an active screening program had better prognosis than those identified in the routine practice [10]. Therefore, in general, an early detection of PAH results in the better outcome in SSc patients.

Multiple screening algorithms to refer for RHC using non-invasive markers have been proposed; the European Society of Cardiology/European Respiratory Society (ESC/ERS) guidelines [11], the Australian Scleroderma Interest Group (ASIG) algorithm [12], recommendations from American College of Rheumatology [13], and the DETECT algorithm [4]. Among these algorithms, DETECT has been well accepted, because of the high sensitivity, and less missed patients with SSc-PAH [14]. Therefore, we evaluated risk factors and established an algorithm to predict borderline PAP referring to the DETECT algorithm. We assessed anti-U1-RNP antibody in addition to anti-centromere antibody, since anti-U1-RNP antibody is another risk of SSc-PAH in Asian population [15]. We also included patients with DLCO of $\geq 60\%$ to evaluate early change of DLCO in early phase of SSc-PAH, whereas the DETECT study excluded those patients.

The novel finding of this study is the elevation of FVC/DLCO in pre- and early stage of SSc-PAH. FVC/DLCO may be sensitive to detect early change of pulmonary blood flow

due to vascular bed impairment, whereas other markers, such as plasma BNP and NT-proBNP levels, reflect cardiac compensation for progressed obstruction of pulmonary vasculatures which occurs after the progression of PAH.

This study had several potential limitations. First, it was conducted at a single center, had a small sample size, and used a retrospective cross-sectional design. Moreover, our study included only Japanese population. Second, this study lacked external validation cohorts. Therefore, further investigations would confirm and polish our pilot algorithm.

We proposed an algorithm to predict mPAP > 20 mmHg in SSc patients with its sensitivity of 87.5% and specificity of 92%. Our data showed that weighting FVC/DLCO and right axis deviation may improve its predictability.

Acknowledgements No specific funding was received to carry out the work described in this manuscript.

Author contributions All authors were involved in drafting the manuscript or revising it critically for important intellectual content, and approved the final version to be submitted for publication. MK had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study conception and design: HN and MK. Acquisition of data: KN, HN, NA, HO, and IT. Analysis and interpretation of data: KN, HN, MK, YF, KO, SY, and TA.

Compliance with ethical standards

Conflict of interest No specific funding was received to carry out the work described in this manuscript. TA reports personal fees from Chugai, during the conduct of the study; grants and personal fees from Astellas, grants and personal fees from Takeda, grants and personal fees from Mitsubishi Tanabe, grants and personal fees from Chugai, grants and personal fees from Pfizer, grants from Daiichi Sankyo, grants from Otsuka, personal fees from Eisai, and personal fees from AbbVie, outside the submitted work. SY reports grants and speaker's fee from Bristol-Myers Squibb Co., Speaker's fee from Chugai, Mitsubishi Tanabe, outside the submitted work. MK reports grants from GSK, grants from Actelion, outside the submitted work. The other authors state that they have no conflict of interest. TA reports personal fees from Chugai, during the conduct of the study; grants and personal fees from Astellas, grants and personal fees from Takeda, grants and personal fees from Mitsubishi Tanabe, grants and personal fees from Chugai, grants and personal fees from Pfizer, grants from Daiichi Sankyo, grants from Otsuka, personal fees from Eisai, and personal fees from AbbVie, outside the submitted work. SY reports grants and speaker's fee from Bristol-Myers Squibb Co., Speaker's fee from Chugai, Mitsubishi Tanabe, outside the submitted work. MK reports grants from GSK, grants from Actelion, outside the submitted work. The other authors state that they have no conflict of interest.

References

1. Tyndall AJ, Bannert B, Vonk M, Airo P, Cozzi F, Carreira PE et al (2010) Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUS-TAR) database. *Ann Rheum Dis* 69(10):1809–1815
2. Morrisroe K, Stevens W, Huq M, Prior D, Sahhar J, Ngian GS et al (2017) Survival and quality of life in incident systemic sclerosis-related pulmonary arterial hypertension. *Arthritis Res Ther* 19(1):122
3. Kato M, Atsumi T (2018) Pulmonary arterial hypertension associated with connective tissue diseases: a review focusing on distinctive clinical aspects. *Eur J Clin Invest* 48(2):e12876
4. Coghlan JG, Denton CP, Grunig E, Bonderman D, Distler O, Khanna D et al (2014) Evidence-based detection of pulmonary arterial hypertension in systemic sclerosis: the DETECT study. *Ann Rheum Dis* 73(7):1340–1349
5. Guillen-Del Castillo A, Callejas-Moraga EL, Garcia G, Rodriguez-Palomares JF, Roman A, Berastegui C et al (2017) High sensitivity and negative predictive value of the DETECT algorithm for an early diagnosis of pulmonary arterial hypertension in systemic sclerosis: application in a single center. *Arthritis Res Ther* 19(1):135
6. Vandecasteele E, Drieghe B, Melsens K, Thevissen K, De Pauw M, Deschepper E et al (2017) Screening for pulmonary arterial hypertension in an unselected prospective systemic sclerosis cohort. *Eur Respir J* 49(5):1–9
7. Valerio CJ, Schreiber BE, Handler CE, Denton CP, Coghlan JG (2013) Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension. *Arthritis Rheum* 65(4):1074–1084
8. Simonneau G, Montani D, Celermajer DS, Denton CP, Gatzoulis MA, Krowka M et al (2019) Haemodynamic definitions and updated clinical classification of pulmonary hypertension. *Eur Respir J* 53(1):1–13
9. Bae S, Saggarr R, Bolster MB, Chung L, Csuka ME, Derk C et al (2012) Baseline characteristics and follow-up in patients with normal haemodynamics versus borderline mean pulmonary arterial pressure in systemic sclerosis: results from the PHAROS registry. *Ann Rheum Dis* 71(8):1335–1342
10. Humbert M, Yaici A, de Groote P, Montani D, Sitbon O, Launay D et al (2011) Screening for pulmonary arterial hypertension in patients with systemic sclerosis: clinical characteristics at diagnosis and long-term survival. *Arthritis Rheum* 63(11):3522–3530
11. Galie N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA et al (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). *Eur Heart J* 30(20):2493–2537
12. Thakkar V, Stevens WM, Prior D, Moore OA, Byron J, Liew D et al (2012) N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study. *Arthritis Res Ther* 14(3):R143
13. Khanna D, Gladue H, Channick R, Chung L, Distler O, Furst DE et al (2013) Recommendations for screening and detection of connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheum* 65(12):3194–3201
14. Hao Y, Thakkar V, Stevens W, Morrisroe K, Prior D, Rabusa C et al (2015) A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis. *Arthritis Res Ther* 17:7
15. Sobanski V, Giovannelli J, Lynch BM, Schreiber BE, Nihtyanova SI, Harvey J et al (2016) Characteristics and survival of anti-U1 RNP antibody-positive patients with connective tissue disease-associated pulmonary arterial hypertension. *Arthritis Rheumatol* 68(2):484–493

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.